UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

Date of report (Date of earliest event reported): May 12, 2014

 

 

TG Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

(State or Other Jurisdiction

of Incorporation)

001-32639

(Commission File Number)

36-3898269

(IRS Employer Identification No.)

 

3 Columbus Circle, 15th Floor

New York, New York 10019

(Address of Principal Executive Offices)

 

(212) 554-4484

(Registrant's telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

£Written communications pursuant to Rule 425 under the Securities Act.
£Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
£Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
£Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On May 12, 2014, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the first quarter ended March 31, 2014. TG also announced that on Tuesday, May 13, 2014 at 8:30am EDT, TG would host an investor conference call during which the Company would discuss the Company’s first quarter 2014 financial results and provide a business outlook for the remainder of 2014. A copy of such press release is being furnished as Exhibit 99.1.

 

Item 9.01 Financial Statements And Exhibits.

 

(d)Exhibits.

 

99.1Press release issued by TG Therapeutics, Inc., dated May 12, 2014.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  TG Therapeutics, Inc.
  (Registrant)
   
   
Date: May 12, 2014 By:  /s/ Sean A. Power
    Sean A. Power
Chief Financial Officer

 

 
 

 

INDEX TO EXHIBITS

 

Exhibit
Number		Description

 

99.1Press release issued by TG Therapeutics, Inc., dated May 12, 2014.